Citigroup
ARTV

Citigroup’s Artiva Biotherapeutics ARTV Stock Holding History

Citigroup’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-105,573
Closed -$303K – 6568
2025
Q3 		$303K Buy
105,573
+102,006
+2,860% +$273K ﹤0.01% 3805
2025
Q2 		$5.39K Sell
3,567
-10,771
-75% -$22.6K ﹤0.01% 5271
2025
Q1 		$43K Sell
14,338
-1,268
-8% -$6.85K ﹤0.01% 4917
2024
Q4 		$157K Buy
15,606
+5,425
+53% +$65.2K ﹤0.01% 4568
2024
Q3 		$157K Buy
+10,181
New +$118K ﹤0.01% 4518

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
Revelation Capital Management Sausalito, California $67.4M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citigroup's ARTV Position: Q4 2025 in Review

Citigroup sold out of Artiva Biotherapeutics (ARTV) in Q4 2025, closing a stake of 105,573 shares — an estimated $303K sold.

Citigroup first reported a position in ARTV in Q3 2024 and held it in 5 quarters. The position peaked at $303K in Q3 2025. 34 funds tracked by Wall St. Rank hold ARTV as of Q4 2025.

  • Citigroup reported no remaining Artiva Biotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 105,573 Artiva Biotherapeutics shares in Q4 2025, an estimated $303K.
  • Citigroup first reported a position in Artiva Biotherapeutics in Q3 2024 and held it in 5 quarters.
  • Citigroup's Artiva Biotherapeutics position peaked at $303K in Q3 2025.
  • 34 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.